Mineralys Therapeutics, Inc. (MLYS) Reports Lorundrostat Cut SBP; 46% Hit <130 mmHg at 12 Weeks
Mineralys Therapeutics (MLYS) reported Phase 3 data showing 46% of patients on lorundrostat 50 mg achieved SBP <130 mmHg at 12 weeks, with 70% seeing ≥10 mmHg reduction. Phase 2 data showed an 11.1 mmHg morning SBP drop at Week 4. The company aims for FDA approval and clear labeling for BP reduction in resistant hypertension.
How this was made
The 30-second read
Why it matters
The data could catalyze a price rally if investors view the results as a step toward FDA approval.
Market read
First disclosure of pivotal trial results; likely to affect MLYS and peers in the hypertension space.
What to watch
Potential safety signals or trial enrollment challenges not disclosed in the brief.
Background
Mineralys Therapeutics released Phase 3 hypertension data via GlobeNewswire.
Ticker impact
Phase 3 data shows 46% of patients on lorundrostat 50 mg achieved SBP <130 mmHg at week 12.
upward pressure as the market prices in the encouraging trial outcomes
First‑time disclosure of late‑stage efficacy data for a hypertension drug; such data historically moves biotech stocks.
Market effects
Strengthens the hypertension‑treatment segment and may boost peer biotech valuations.
U.S. biotech sector sees modest uplift.
Limited to investors tracking late‑stage drug trials.
Counterpoint
Skeptics may question durability of BP reduction and await FDA review before committing.
Key entities
- companyMineralys Therapeutics, Inc.
Biopharma developing lorundrostat for resistant hypertension.
